ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0813

Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study

Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Sang Hee Park2, Xue Han2, Ying Shan1, Carla Roberts-Toler1, Nicole Middaugh1 and Vadim Khaychuk2, 1CorEvitas, LLC, Waltham, MA, 2Bristol Myers Squibb, Princeton, NJ

Meeting: ACR Convergence 2021

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Biologicals, Disease Activity, registry, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the effectiveness of specific drugs as first or later lines of therapy will help inform treatment sequencing. Data from patients enrolled in the Corrona RA Registry network were used to compare the effectiveness of abatacept across lines of therapy overall (primary cohort) and in a subset of patients who were ACPA+.

Methods: Patients with RA who initiated abatacept (January 2006 to October 2020), had 6 months’ follow-up (within 4−9 months of starting abatacept), had baseline (BL) and follow-up CDAI scores available, and had BL CDAI > 2.8 were included. Outcomes were compared for first-, second- and third or higher-line therapy: 0, 1 or ≥ 2 prior biologic DMARDs or Janus kinase inhibitors, respectively. Continuous outcomes included change from BL to 6 months in mean CDAI and patient-reported pain, fatigue, and HAQ. Binary outcomes included rate of achieving minimal clinically important difference (MCID) in CDAI or modified ACR20/50/70 at 6 months. Continuous and binary outcomes were analyzed using multiple linear and logistic regression, respectively. The models included line of therapy, age, sex, disease duration, work status, SC nodules, history of hypertension and depression, BL CDAI, BL patient-reported pain, and BL fatigue. Additional subgroup analyses were carried out in patients with moderate/high disease activity (CDAI > 10) at BL.

Results: In total, 2876 patients (2327 with BL CDAI > 10; 890 ACPA+) were included; 442, 911, and 1523 patients initiated first-, second- or third/higher-line abatacept, respectively. Compared with patients on second/third/higher-line abatacept therapy, those on first-line abatacept were significantly older, had shorter disease duration, and had lower BL CDAI, pain and fatigue (all P < 0.001). In adjusted analyses, patients receiving abatacept as earlier lines of therapy had significantly greater improvement from BL in mean CDAI and in patient-reported fatigue and HAQ (Table 1). There was no significant difference between lines of therapy in change in patient-reported pain. Patients receiving first-line abatacept had significantly higher odds of achieving a MCID in CDAI or modified ACR20/50/70 response (Figure 1). Similar patterns were seen when the sample was limited to patients with moderate/high disease activity or in patients who were ACPA+.

Conclusion: There were significant differences in improvement in clinical disease activity and patient-reported outcomes across lines of therapy. Better treatment responses were observed with earlier lines of abatacept therapy in the overall population, in patients who were ACPA+ and in those with moderate/high BL disease activity.

References:
1. Harrold LR, et al. Clin Rheumatol 2017;36:1215−1220.
2. Monti S, et al. RMD Open 2015;1(Suppl 1):e000057.
Medical writing: Claire Line, PhD (Caudex), funded by Bristol Myers Squibb
Original abstract © 2020 EULAR/BMJ


Disclosures: L. Harrold, Bristol Myers Squibb, 2; K. Wittstock, Bristol Myers Squibb, 3, 11; S. Kelly, Bristol Myers Squibb, 3; S. Park, Bristol Myers Squibb, 3; X. Han, Bristol Myers Squibb, 3; Y. Shan, CorEvitas, 3; C. Roberts-Toler, CorEvitas, 3; N. Middaugh, None; V. Khaychuk, Bristol Myers Squibb, 3.

To cite this abstract in AMA style:

Harrold L, Wittstock K, Kelly S, Park S, Han X, Shan Y, Roberts-Toler C, Middaugh N, Khaychuk V. Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/improvement-in-clinical-disease-activity-and-patient-reported-outcomes-after-6-months-of-treatment-with-abatacept-stratified-by-line-of-therapy-in-patients-with-ra-results-from-a-large-us-nationa/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-clinical-disease-activity-and-patient-reported-outcomes-after-6-months-of-treatment-with-abatacept-stratified-by-line-of-therapy-in-patients-with-ra-results-from-a-large-us-nationa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences